• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

CeQur raises $115M for wearable insulin delivery device

April 13, 2021 By Sean Whooley

CeQur

CeQur announced today that it closed an oversubscribed equity financing round with proceeds of $115 million. Lucerne, Switzerland/Marlborough, Mass.–based CeQur said in a news release that it plans to use the funds to advance the commercial plans for the CeQur Simplicity wearable insulin delivery device. The company’s plans include market development, a phased commercial launch […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Patient Monitoring, Pharmaceuticals Tagged With: cequr, Tandem Diabetes Care

Terumo launches therapeutic interventional oncology team

April 13, 2021 By Sean Whooley

Terumo

Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival. Team members work in […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Terumo Corp.

GH Research closes $125M oversubscribed Series B

April 13, 2021 By Sean Whooley

GH_Research_Logo

GH Research Ireland announced that it closed an oversubscribed Series B financing round with proceeds of $125 million. Dublin, Ireland-based GH develops the GH001 therapeutic, a drug product for 5-MeO-DMT administration through a proprietary inhalation approach. A Phase 1 healthy volunteer trial showed GH001 to be well-tolerated while defining a dose range and individualized dosing […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Neurological, Pharmaceuticals Tagged With: GH Research

BioCorp, Roche launch Mallya smart insulin pen in France

April 13, 2021 By Sean Whooley

BioCorp Roche

BioCorp and Roche Diabetes Care France announced the launch of the Mallya smart insulin pen device in France. Developed by BioCorp, Mallya is an intelligent sensor for insulin injection pens that has CE mark approval in Europe. The platform is compatible with any disposable insulin pen. It enables reliable monitoring for doses selected for injection and it offers […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: biocorp, Roche

Genentech wins FDA approval for Xolair prefilled syringe

April 12, 2021 By Sean Whooley

Genentech logo updated

Genentech announced today that the FDA approved its supplemental biologics license application for the Xolair prefilled syringe. South San Francisco-based Genentech touts the Xolair (omalizumab) prefilled syringe for self-injection across all approved U.S. indications as the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for treating moderate to severe persistent allergic asthma, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: FDA, Genentech

Lyra Therapeutics touts results from chronic rhinosinusitis treatment trial

April 12, 2021 By Sean Whooley

Lyra Therapeutics LYR-210

Lyra Therapeutics (NSDQ:LYRA) presented positive results from a Phase 2 study of its therapeutic for treating chronic rhinosinusitis (CRS). Watertown, Mass.-based Lyra’s Phase 2 Lantern study evaluated its LYR-210 long-acting product for CRS, which is administered in-office to deliver a sustained release for up to six months as a non-invasive alternative to surgery for patients […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat Tagged With: Lyra Therapeutics

TriSalus, University of Texas to collaborate on solid tumor treatment study

April 8, 2021 By Sean Whooley

TriSalus-logo

TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: trisaluslifesciences, University of Texas MD Anderson Cancer Center

Teva Pharmaceuticals receives European approval for Spiromax inhalers

April 8, 2021 By Sean Whooley

Teva

Teva Pharmaceuticals announced today that it received European marketing authorization for its Seffalair and BroPair Spiromax inhalers. Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) received approval as a maintenance treatment for asthma in adults and adolescents aged 12 years and older, according to a news […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: Teva, Teva Pharmaceuticals

Medtronic commits to helping people of color with diabetes

April 7, 2021 By Sean Whooley

Medtronic logo updated

Medtronic (NYSE:MDT) announced today that it entered multiple partnerships to help improve health equity for people of color living with diabetes. Fridley, Minn.-based Medtronic committed investments in partnerships with the American Diabetes Association (ADA) and the T1D Exchange, along with additional research efforts, to better understand and address such disparities, according to a news release. Get […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup Tagged With: American Diabetes Association, Medtronic

Better Therapeutics to go public via $113M merger with SPAC

April 7, 2021 By Sean Whooley

Better Therapeutics

Better Therapeutics announced today that, through a $113 million merger with Mountain Crest Acquisition Corp II, it will go public. Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), will acquire Better Therapeutics in a deal expected to be completed in the summer of this year, with the company continuing to operate as Better Therapeutics […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Better Therapeutics, Mountain Crest SPAC

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 28
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS